People · Operator
Named in public records as an officer, director or promoter · active 2010–2022 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Velomedix, Inc. | — | Biotechnology | Series A | $27.3M | $335.9M | 2010 |
| Aegea Medical Inc | — | Other Health Care | Series A | $23.4M | $121.1M | 2011 |
| Optofluidics, Inc. | — | Biotechnology | Series A | $19.4M | $96.6M | 2020 |
Casey McGlynn at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Casey McGlynn on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Daniel Burnett | 1 | 11 |
| William Snider | 1 | 7 |
| J. Casey McGlynn | 1 | 5 |
| John Dean | 1 | 5 |
| David Douglass | 1 | 5 |
| Andrew Cleeland | 1 | 5 |
| Joseph Keegan | 1 | 4 |
| Michael Hoey | 1 | 4 |
| Chad Souvignier | 1 | 4 |
| DOUG KELLY | 1 | 4 |
| Shahram Hejazi | 1 | 3 |
| John Beck | 1 | 3 |
| Ken Ludlum | 1 | 3 |
| Douglas Kelly | 1 | 3 |
| Charles Carignan | 1 | 3 |
| Marc Galletti | 1 | 2 |
| Robert Wicke | 1 | 2 |
| ROBERT HART | 1 | 2 |
| Jeff Gold | 1 | 2 |
| Paul Goeld | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.